Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 19, 2019 - Issue 1
Submit an article Journal homepage
124
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Factors associated with physicians’ decision to discontinue or down-titrate sulfonylureas for type 2 diabetes patients

Pedro LairesMerck & Co., Inc., Kenilworth, NJ, USAView further author information
,
Karen KurtykaMerck & Co., Inc., Kenilworth, NJ, USAView further author information
,
Edward A. WittKantar Health, Princeton, NJ, USAView further author information
,
Ying QiuMerck & Co., Inc., Kenilworth, NJ, USAView further author information
,
Shengsheng YuMerck & Co., Inc., Kenilworth, NJ, USAView further author information
&
Kristy IglayMerck & Co., Inc., Kenilworth, NJ, USACorrespondence[email protected]
View further author information
Pages 71-79 | Received 30 Mar 2018, Accepted 08 Aug 2018, Published online: 26 Sep 2018

References

  • Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nat Rev Endocrinol. 2012;8:639–649.
  • Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States. Atlanta (GA): National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation; 2014.
  • Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta (GA): National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation; 2011.
  • Mokdad A, Ford E, Bowman B, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–79.
  • Malik VS, Popkin BM, Bray GA, et al. Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk. Circulation. 2010;121:1356–1364.
  • Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234.
  • Molitch ME. Current state of type 2 diabetes management. Am J Manag Care. 2013;19:S136–S142.
  • Krentz DAJ, Bailey CJ. Oral antidiabetic agents. Drugs. 2005;65:385–411.
  • Kimmel B, Inzucchi SE. Oral agents for type 2 diabetes: an update. Clin Diabetes. 2005;23:64–76.
  • DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281–303.
  • Hanefeld M. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. Int J Clin Pract. 2007;61:20–27.
  • Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137:25–33.
  • Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342–1349.
  • Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15:938–953.
  • Phung OJ, Schwartzman E, Allen RW, et al. Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med. 2013;30:1160–1171.
  • Edridge CL, Dunkley AJ, Bodicoat DH, et al. Prevalence and incidence of hypoglycaemia in 532,542 people with type 2 diabetes on oral therapies and insulin: a systematic review and meta-analysis of population based studies. PLoS One. 2015;10:e0126427.
  • Grant RW, Wexler DJ, Watson AJ, et al. How doctors choose medications to treat type 2 diabetes a national survey of specialists and academic generalists. Diabetes Care. 2007;30:1448–1453.
  • Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283:1695–1702.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.